FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: A pooled analysis of 29 published trials

Clinical Colorectal Cancer

Volumn 12, Issue 3, 2013, Pages 145-151

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Lonati, Veronica ^a   Maspero, Federica ^a   Sauta, Maria Grazia ^b   Beretta, Giordano Domenico ^b   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Colorectal cancer; First line; FOLFIRI

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADVANCED CANCER; ADVERSE OUTCOME; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LIVER RESECTION; METASTASIS; METASTASIS RESECTION; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

BEVACIZUMAB; CHEMOTHERAPY; COLORECTAL CANCER; FIRST LINE; FOLFIRI;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; TREATMENT OUTCOME;

EID: 84883138328     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.04.006     Document Type: Review

References (39)

1. E. Van Cutsem, C.H. Köhne, and I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 20 29 2011 2011 2019
2. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335
3. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786
4. C.S. Fuchs, J. Marshall, and J. Barrueco Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 2008 689 690
5. A. Sobrero, S. Ackland, and S. Clarke Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 2009 113 119 Epub 2009 Jul 23. Erratum in: Oncology. 2009;77:following 119. Chiara, Silvia [corrected to Chiara, Silvana]. Oncology 2009; 77:256
6. L.B. Saltz, S. Clarke, and E. Díaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019 Erratum in: J Clin Oncol 2008; 26:3110. J Clin Oncol 2009; 27:653
7. J.D. Berlin, J.C. Bendell, and L.L. Hart A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer Clin Cancer Res 19 2013 258 267
8. J.C. Bendell, T.S. Bekaii-Saab, and A.L. Cohn Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study Oncologist 17 2012 1486 1495
9. B. Budai, T. Nagy, and I. Láng The use of high dose d, l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab Angiogenesis 16 2013 113 121
10. S. Stintzing, and L. Fischer von Weikersthal FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 Ann Oncol 23 2012 1693 1699
11. D. Pectasides, G. Papaxoinis, and K.T. Kalogeras XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis BMC Cancer 12 2012 271
12. U. Varol, B. Karaca, and B. Cakar Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis Am J Clin Oncol 2012 May 24 [Epub ahead of print]
13. J. Souglakos, N. Ziras, and S. Kakolyris Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Br J Cancer 106 2012 453 459
14. T. Nishi, Y. Hamamoto, and E. Warita Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma Int J Clin Oncol 16 2011 488 493
15. F. Loupakis, A. Ruzzo, and L. Salvatore Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer BMC Cancer 11 2011 247
16. J. Ocvirk, M. Rebersek, and M. Boc Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI Anticancer Res 31 2011 1777 1782
17. H. Odabas, N. Ozdemir, and H. Abali First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab J BUON 16 2011 247 252
18. R. López, M. Salgado, and M. Reboredo A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer Br J Cancer 103 2010 1536 1541
19. G. Dranitsaris, S. Edwards, and J. Edwards Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador Curr Oncol 17 2010 12 16
20. S. Kopetz, P.M. Hoff, and J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
21. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
22. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
23. G. Rosati, S. Cordio, and H.S. Parra Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study Invest New Drugs 30 2012 1978 1983
24. H. Andoh, S. Kato, and M. Gamoh A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 plus bevacizumab (IRIS+BV) and modified FOLFIRI plus BV (mFOLFIRI+BV) in patients (pts) with metastatic colorectal cancer (mCRC): The result of efficacy report of T-CORE0702 J Clin Oncol 29 suppl 2011 abstract e14001. Available at: http://www.asco.org Accessed: April 28, 2013
25. Z. Rakusic, F. Santek, and M. Basic-Koretic FOLFIRI vs FOLFIRI 1 bevacizumab in first-line therapy of metastatic colorectal cancer: retrospective analysis of 81 patients in our institution Ann Oncol 21 suppl 8 2010 217 (abstract 680)
26. D. Smith, M. Rouyer, and Y. Becouarn Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study J Clin Oncol 28 suppl 2010 abstract e14075.
27. J.P. Metges, E. Gamelin, and R. Faroux Management of unresectable metastatic colorectal cancer (MRCC) in the real world with successive regimens with targeted therapies (bevacizumab and cetuximab): the experience of the OMIT Bretagne Pays de Loire Eur J Cancer 7 suppl 2009 209
28. R. De Sanctis, F. Longo, and B. Gori Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: single center experience Ann Oncol 19 suppl 2008 viii, 145
29. M. Ducreux, A. Adenis, and J. Mendiboure Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) J Clin Oncol 27 suppl 2009 abstract 4086). Available at: http://www.asco.org Accessed: April 29, 2013
30. A. Ruiz De Lobera Martinez, I. Marrodan Ciordia, and E. Azkona Uribelarrea First line treatment with FOLFIRI-bevacizumab for advanced colorectal cancer (ACRC): a single institution experience with 127 consecutive unselected patients Eur J Cancer 7 suppl 2009 342 Supplement
31. S. Tomao, G. Spinelli, and L. Rossi Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer J Clin Oncol 27 suppl 2009 abstract e15138. Available at: http://www.asco.org Accessed: April 29, 2013
32. F. Giuliani, F. De Vita, and V. Lorusso FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): final results (prot. GOIM 2601) J Clin Oncol 27 suppl 2009 abstract e15007. Available at: http://www.asco.org Accessed: April 29, 2013
33. M. Kozloff, M.U. Yood, and J. Berlin Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 2009 862 870
34. J.A. Meyerhardt, L. Li, and H.K. Sanoff Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer J Clin Oncol 30 2012 608 615
35. F. Petrelli, and S. Barni Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis Int J Colorectal Dis 27 2012 997 1004
36. L.T. Macedo, A.B. da Costa Lima, and A.D. Sasse Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups BMC Cancer 12 2012 89
37. S. Whyte, A. Pandor, and M. Stevenson Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal Pharmacoeconomics 30 2012 1119 1132
38. F. Petrelli, and S. Barni Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 24 2013 186 192
39. A. Okines, O.D. Puerto, and D. Cunningham Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized phase-III NO16966 trial Br J Cancer 101 2009 1033 1038